Brief: FDA Grants Regenerative Medicine Advanced Therapy Designation To Autolus’ Car T Cell Therapy
25/04/2022 12:17
April 25 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* FDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO
AUTOLUS’
CAR T CELL THERAPY, OBE-CEL, FOR THE TREATMENT OF ADULT B-ALL
Source text for Eikon: ID:nGNX3Dfn4c
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants